[1] Yonekawa T, Murai H, Utsuki S,et al. A nationwide survey of hypertrophic pachymeningitis in Japan[J]. J Neurol Neurosurg Psychiatry,2014,85(7):732-739.DOI: 10.1136/jnnp-2013-306410.
[2] Chen H, Zhang W, Jing J,et al. The clinical and imaging features of hypertrophic pachymeningitis: a clinical analysis on 22 patients[J]. Neurol Sci,2019,40(2):269-274.DOI: 10.1007/s10072-018-3619-4.
[3] 徐肖,狄晴,张玲如,等. 肥厚性硬脑膜炎的临床、影像学及病理学特征[J]. 临床神经病学杂志,2009,22(6):461-463.
[4] Ranasinghe MG, Zalatimo O, Rizk E,et al. Idiopathic hypertrophic spinal pachymeningitis[J]. J Neurosurg Spine,2011,15(2):195-201.DOI: 10.3171/2011.4.SPINE1037.
[5] 叶锦龙,张伟劲,刘宝珠,等. 血清IgG4水平升高的肥厚性硬脑膜炎患者的临床特征分析[J]. 国际医药卫生导报,2022,28(15):2166-2169. DOI:10.3760/cma.j.issn.1007-1245. 2022.15.021.
[6] Shi CH, Niu ST, Zhang ZQ. Clinical image and pathology of hypertrophic cranial pachymeningitis[J]. Genet Mol Res,2014,13(4):10501-10509.DOI: 10.4238/2014.December.12.11.
[7] Bi Z, Shang K, Cao J,et al. Hypertrophic pachymeningitis in Chinese patients: presentation, radiological findings, and clinical course[J]. Biomed Res Int,2020,2020:2926419.DOI: 10.1155/2020/2926419.
[8] Zhao M, Geng T, Qiao L,et al. Idiopathic hypertrophic pachymeningitis: clinical, laboratory and neuroradiologic features in China[J]. J Clin Neurosci,2014,21(7):1127-1132.DOI: 10.1016/j.jocn.2013.09.025.
[9] Umehara H, Okazaki K, Kawa S,et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD[J]. Mod Rheumatol,2021,31(3):529-533.DOI: 10.1080/14397595.2020.1859710.
[10] Yokoseki A, Saji E, Arakawa M,et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody[J]. Brain,2014,137(Pt 2):520-536.DOI: 10.1093/brain/awt314.
[11] Khosroshahi A, Wallace ZS, Crowe JL,et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol,2015,67(7):1688-1699.DOI: 10.1002/art.39132.
[12] Okazaki K, Kawa S, Kamisawa T,et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020[J]. J Gastroenterol,2022,57(4):225-245.DOI: 10.1007/s00535-022-01857-9.
[13] Lu LX, Della-Torre E, Stone JH,et al. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment[J]. JAMA Neurol,2014,71(6):785-793.DOI: 10.1001/jamaneurol.2014.243.
|